Zolgensma Provides No Proven Benefit Over Spinraza In SMA, Says German HTA
IQWiG Laments Lack Of Comparative Data
IQWiG, Germany’s health technology appraisal institute, has found that Novartis’s gene therapy Zolgensma offers no additional benefit compared with Biogen’s Spinraza for treating spinal muscular atrophy, while Roche’s Evrysdi offers a hint of benefit in one patient group.
